Publications by authors named "Titus Watrin"

Claim this Profile
T
The tumor microenvironment in hairy cell leukemia (HCL) and splenic B cell lymphoma with prominent nucleoli (SBLPN).
Titus Watrin, Marc Seifert, Sascha Dietrich

Leuk Lymphoma· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Haploidentical Allogeneic Stem Cell Transplantation as a Superior Alternative for Patients With Mismatch Donors-A Single Center Experience in 152 Patients.
Paul Jäger, Benno Biermann, Nora Liebers, Felicitas Schulz, Ben-Niklas Baermann, Titus Watrin

EJHaem· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deciphering the Therapeutic Potential of Novel Pentyloxyamide-Based Class I, IIb HDAC Inhibitors against Therapy-Resistant Leukemia.
Fabian Fischer, Julian Schliehe-Diecks, Jia-Wey Tu, Tanja Gangnus, Yu Lin Ho, Titus Watrin

J Med Chem· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergistic drug interactions of the histone deacetylase inhibitor givinostat (ITF2357) in CRLF2-rearranged pediatric B-cell precursor acute lymphoblastic leukemia identified by high-throughput drug screening.
Athanasios Oikonomou, Titus Watrin, Luigia Valsecchi, Katerina Scharov, Angela Maria Savino

Heliyon· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia.
Athanasios Oikonomou, Luigia Valsecchi, Manuel Quadri, Titus Watrin, Katerina Scharov

Biochem Pharmacol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recurrent Germline Variant in Predisposes Children to Lymphoblastic Leukemia or Lymphoma.
Anne Schedel, Ulrike Anne Friedrich, Mina N F Morcos, Rabea Wagener, Juha Mehtonen, Titus Watrin

Int J Mol Sci· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
Sarah B Reusing, Dan A Vallera, Angela R Manser, Titus Watrin, Sanil Bhatia

Cancer Immunol Immunother· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis